These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 28880016)

  • 1. (5R)-5-hydroxytriptolide ameliorates anti-glomerular basement membrane glomerulonephritis in NZW mice by regulating Fcγ receptor signaling.
    Qi Q; Li H; Lin ZM; Yang XQ; Zhu FH; Liu YT; Shao MJ; Zhang LY; Xu YS; Yan YX; Sun LL; He SJ; Tang W; Zuo JP
    Acta Pharmacol Sin; 2018 Jan; 39(1):107-116. PubMed ID: 28880016
    [TBL] [Abstract][Full Text] [Related]  

  • 2. (5R)-5-hydroxytriptolide ameliorates lupus nephritis in MRL/
    Zhang LY; Li H; Wu YW; Cheng L; Yan YX; Yang XQ; Zhu FH; He SJ; Tang W; Zuo JP
    Am J Physiol Renal Physiol; 2017 Apr; 312(4):F769-F777. PubMed ID: 28100505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. (5R)-5-hydroxytriptolide attenuated collagen-induced arthritis in DBA/1 mice via suppressing interferon-gamma production and its related signaling.
    Zhou R; Tang W; Ren YX; He PL; Zhang F; Shi LP; Fu YF; Li YC; Ono S; Fujiwara H; Yang YF; Zuo JP
    J Pharmacol Exp Ther; 2006 Jul; 318(1):35-44. PubMed ID: 16574782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. (5R)-5-hydroxytriptolide (LLDT-8), a novel triptolide derivative, prevents experimental autoimmune encephalomyelitis via inhibiting T cell activation.
    Fu YF; Zhu YN; Ni J; Zhong XG; Tang W; Zhou R; Zhou Y; Dong JR; He PL; Wan H; Li YC; Yang YF; Zuo JP
    J Neuroimmunol; 2006 Jun; 175(1-2):142-51. PubMed ID: 16712960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. (5R)-5-hydroxytriptolide (LLDT-8), a novel triptolide analog mediates immunosuppressive effects in vitro and in vivo.
    Zhou R; Zhang F; He PL; Zhou WL; Wu QL; Xu JY; Zhou Y; Tang W; Li XY; Yang YF; Li YC; Zuo JP
    Int Immunopharmacol; 2005 Dec; 5(13-14):1895-903. PubMed ID: 16275624
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preventive effects of (5R)-5-hydroxytriptolide on concanavalin A-induced hepatitis.
    Zhou R; Tang W; Ren YX; He PL; Yang YF; Li YC; Zuo JP
    Eur J Pharmacol; 2006 May; 537(1-3):181-9. PubMed ID: 16603150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. (5R)-5-hydroxytriptolide inhibits IFN-gamma-related signaling.
    Zhou R; Wang JX; Tang W; He PL; Yang YF; Li YC; Li XY; Zuo JP
    Acta Pharmacol Sin; 2006 Dec; 27(12):1616-21. PubMed ID: 17112417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. (5R)-5-Hydroxytriptolide (LLDT-8) inhibits osteoclastogenesis via RANKL/RANK/OPG signaling pathway.
    Shen Y; Jiang T; Wang R; He S; Guo M; Zuo J; He D
    BMC Complement Altern Med; 2015 Mar; 15():77. PubMed ID: 25887296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suppression of (5R)-5-hydroxytriptolide (LLDT-8) on allograft rejection in full MHC-mismatched mouse cardiac transplantation.
    Tang W; Zhou R; Yang Y; Li YC; Yang YF; Zuo JP
    Transplantation; 2006 Mar; 81(6):927-33. PubMed ID: 16570019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Triptolide analog LLDT-8 ameliorates psoriasis-like dermatitis in BALB/c mice via suppressing the IL-36α signaling pathway.
    Qi Q; Li Q; Zhu H; Lu H; Yang X; Wu Y; Feng C; Fan C; Li H; Wu B; Gao Y; Zhang Z; Zhou H; Zuo J; Tang W
    Pharmacol Res; 2021 Jul; 169():105678. PubMed ID: 34015449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LLDT-8 protects against cerebral ischemia/reperfusion injury by suppressing post-stroke inflammation.
    Chen Y; Zhang L; Ni J; Wang X; Cheng J; Li Y; Zhen X; Cao T; Jia J
    J Pharmacol Sci; 2016 Jun; 131(2):131-7. PubMed ID: 27286958
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of inducible nitric-oxide synthase expression by (5R)-5-hydroxytriptolide in interferon-gamma- and bacterial lipopolysaccharide-stimulated macrophages.
    Zhou R; Zheng SX; Tang W; He PL; Li XY; Yang YF; Li YC; Geng JG; Zuo JP
    J Pharmacol Exp Ther; 2006 Jan; 316(1):121-8. PubMed ID: 16166270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protective role of (5R)-5-hydroxytriptolide in lipopolysaccharide-induced acute lung injury by suppressing dendritic cell activation.
    Chen Y; Kuang Z; Wei W; Hu Y; Mu S; Ding H; Han Y; Tong C; Yang Y; Song Z
    Int Immunopharmacol; 2022 Jan; 102():108410. PubMed ID: 34865994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of graft-versus-host disease by a novel immunosuppressant, (5R)-5-hydroxytriptolide (LLDT-8), through expansion of regulatory T cells.
    Tang W; Yang Y; Zhang F; Li YC; Zhou R; Wang JX; Zhu YN; Li XY; Yang YF; Zuo JP
    Int Immunopharmacol; 2005 Dec; 5(13-14):1904-13. PubMed ID: 16275625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predominant role of FcgammaRIII in the induction of accelerated nephrotoxic glomerulonephritis.
    Fujii T; Hamano Y; Ueda S; Akikusa B; Yamasaki S; Ogawa M; Saisho H; Verbeek JS; Taki S; Saito T
    Kidney Int; 2003 Oct; 64(4):1406-16. PubMed ID: 12969160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. (5R)-5-hydroxytriptolide inhibits the immune response of human peripheral blood mononuclear cells.
    Zhou R; Tang W; He PL; Yang YF; Li YC; Zuo JP
    Int Immunopharmacol; 2009 Jan; 9(1):63-9. PubMed ID: 18952005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Experimental autoimmune anti-glomerular basement membrane glomerulonephritis: a protective role for IFN-gamma.
    Kitching AR; Turner AL; Semple T; Li M; Edgtton KL; Wilson GR; Timoshanko JR; Hudson BG; Holdsworth SR
    J Am Soc Nephrol; 2004 Jul; 15(7):1764-74. PubMed ID: 15213264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ribosomal protein S19 is a novel therapeutic agent in inflammatory kidney disease.
    Lv J; Huang XR; Klug J; Fröhlich S; Lacher P; Xu A; Meinhardt A; Lan HY
    Clin Sci (Lond); 2013 May; 124(10):627-37. PubMed ID: 23252627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Abolition of anti-glomerular basement membrane antibody-mediated glomerulonephritis in FcRgamma-deficient mice.
    Wakayama H; Hasegawa Y; Kawabe T; Hara T; Matsuo S; Mizuno M; Takai T; Kikutani H; Shimokata K
    Eur J Immunol; 2000 Apr; 30(4):1182-90. PubMed ID: 10760808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suppression of experimental crescentic-type anti-glomerular basement membrane (GBM) nephritis by FK506 (tacrolimus hydrate) in rats.
    Hayashi K; Nagamatsu T; Ito M; Suzuki Y
    Jpn J Pharmacol; 1996 Jan; 70(1):43-54. PubMed ID: 8822088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.